Effect of Cabergoline on biochemical and anthropometric parameters of patients with prediabetes.

Evaluating the Effect of Cabergoline on insulin resistance and anthropometric parameters in patients with Impaired fasting glucose and/or Impaired glucose tolerance, a randomized, blinded clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170608034390N6

Enrollment

Registered

2020-05-06

Start date

2016-05-04

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired Glucose Tolerance/Impaired Fasting Glucos. Impaired glucose tolerance (oral)

Interventions

Intervention 1: Intervention group: cabergoline 0.5 mg tablets twice weekly. Intervention 2: Control group: cabergoline 0.5 mg placebo tablets twice weekly.

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with Impaired Fasting Glucose and/or Impaired Glucose Tolerance Adults (18-65 years)

Exclusion criteria

Exclusion criteria: Severe hepatic failure (Child-Pugh scores of 10 or higher) History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders Hypersensitivity to ergot derivatives Uncontrolled hypertension Diabetes Pregnant Women Lactating Women Major psychiatric disorders Patients who are receiving medications which affect prolactin secretion Bulimia or/and anorexia nervosa

Design outcomes

Primary

Measure	Time frame
Fasting Plasma Glucose. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Autoanalyzer.;2h plasma glucose. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: ???????????.;Hb A1c. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: HPLC.;2h Insulin. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: ??????.;Wheight. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Scale.;Height. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Standard Meter.;Wrist circumference. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Standard Meter.	—

Measure

Time frame

Fasting Plasma Glucose. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Autoanalyzer.;2h plasma glucose. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: ???????????.;Hb A1c. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: HPLC.;2h Insulin. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: ??????.;Wheight. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Scale.;Height. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Standard Meter.;Wrist circumference. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Standard Meter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Esmaily

Shahid Beheshti University of Medical Sciences

Esmaily_hadi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026